Findings showed datopotamab deruxtecan significantly improved PFS and OS vs chemotherapy. Topline data were announced from a phase 3 trial evaluating datopotamab deruxtecan-dlnk as a first-line ...
The final overall survival (OS) results of the FLAURA2 trial support osimertinib plus chemotherapy as the new first-line standard of care for EGFR-mutated non-small cell lung cancer (NSCLC), according ...
At its 2009 launch, Chrome OS seemed like a browser with a case of megalomania. Why would Google launch a second operating system when Android was on a path to become the world’s most popular ...
In 2018, Microsoft canceled plans to ship a new Windows-based OS designed from the ground up for a new dual-screen phone form factor, codenamed Andromeda. This special version of Windows would have ...
First-line osimertinib (Tagrisso) plus chemotherapy significantly improved survival versus osimertinib monotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). Among a ...